- Home
- SION vs ALT Comparison
SION vs ALT Comparison
Compare SION & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SION
- ALT
- Stock Information
- Founded
- SION 2019
- ALT 1997
- Country
- SION United States
- ALT United States
- Employees
- SION N/A
- ALT N/A
- Industry
- SION
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- SION
- ALT Health Care
- Exchange
- SION NYSE
- ALT Nasdaq
- Market Cap
- SION 564.4M
- ALT 472.3M
- IPO Year
- SION 2025
- ALT N/A
- Fundamental
- Price
- SION $14.49
- ALT $7.03
- Analyst Decision
- SION Strong Buy
- ALT Strong Buy
- Analyst Count
- SION 1
- ALT 7
- Target Price
- SION $32.00
- ALT $21.00
- AVG Volume (30 Days)
- SION 124.0K
- ALT 3.5M
- Earning Date
- SION 05-12-2025
- ALT 08-07-2025
- Dividend Yield
- SION N/A
- ALT N/A
- EPS Growth
- SION N/A
- ALT N/A
- EPS
- SION N/A
- ALT N/A
- Revenue
- SION N/A
- ALT $20,000.00
- Revenue This Year
- SION N/A
- ALT N/A
- Revenue Next Year
- SION N/A
- ALT $1,557,547.90
- P/E Ratio
- SION N/A
- ALT N/A
- Revenue Growth
- SION N/A
- ALT N/A
- 52 Week Low
- SION $7.26
- ALT $3.55
- 52 Week High
- SION $25.19
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- SION N/A
- ALT 66.62
- Support Level
- SION N/A
- ALT $6.61
- Resistance Level
- SION N/A
- ALT $7.48
- Average True Range (ATR)
- SION 0.00
- ALT 0.53
- MACD
- SION 0.00
- ALT 0.10
- Stochastic Oscillator
- SION 0.00
- ALT 79.32
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.